The Burrill Personalized Medicine Meeting'09 Agenda
Monday, November 9, 2009
Day 1 Focus: Impediments of Personalized Medicine
7:30 – 8:30 a.m.
Breakfast & Registration
8:30 – 10:00 a.m.
Welcome and Personalized Medicine Industry Update
An overview of the state of the biotech industry and personalized medicine in the context of a turbulent, challenging economy.
G. Steven Burrill, CEO, Burrill & Company (Confirmed)
10:00 – 10:30 a.m.
10:30 – 11:45 a.m.
Panel: What does it take to get doctors to adopt personalized medicine?
This panel will discuss how physicians are employing personalized medicine today in the clinic. What value does it have to patients? Can personalized medicine be adopted in the context of today’s healthcare and reimbursement systems? What needs to happen to accelerate adoption by physicians?
- Jim Peters, Managing Partner, Geisinger Ventures - MyCode project (Confirmed)
- Joseph D. McInerney, Executive Director, National Coalition of Health Professional Education in Genetics (Confirmed)
- Dr. Geoffrey Ginsburg, Director, Center for Genomic Medicine at Duke University, Professor of Medicine (Confirmed)
Moderator: David Ewing Duncan, Science Journalist; Author: "Masterminds: Genius, DNA, and the Quest to Rewrite Life"; and Director, Center for Life Sciences, UC Berkeley (Confirmed)
11:45 a.m. – 1:15 p.m.
‘Conversations with Experts’ Luncheon
Informal discussions on business, economic, political and therapeutic topics with an international group of personalized medicine leaders from corporate, academic and government sectors.
- John Climaco, President & CEO, Axial Biotech
- David Ewing Duncan, Science Journalist; Author: "Masterminds: Genius, DNA, and the Quest to Rewrite Life"; and Director, Center for Life Sciences, UC Berkeley
- Jonathan Jacoby – CEO RARE Project
- Emil Kakkis – Kakkis Foundation
- Stephen Little, CEO, DxS Diagnostic Innovations
- Gerald McDougall, Partner, PricewaterhouseCoopers Health Science Practice
- Pratik Multani, Vice President of Clinical Development, Fate Therapeutics
- Brad Popovich, President and Chief Executive Officer, Sirius Genomics, Inc.
- Ms. Na Ree Sørensen, Special Advisor - Life Sciences, Invest in Denmark - Ministry of Foreign Affairs of Denmark
- Dean Sproles, CEO, Iverson Genetic Diagnostics, Inc.
1:15 – 2:15 p.m.
Keynote: Regulatory Perspectives and Government Initiatives
Personalized medicine is not pre-programmed for adoption into clinical practice and it will require changes in regulation, and legislative protections for privacy. It is clear that in order for personalized medicine to maintain its momentum governments will have to play a bigger role in funding and coordinating research while also eliminating regulatory hurdles that currently hinder the creation and adoption of innovative products and medical treatments.
Dr. Margaret “Peggy” Hamburg, Commissioner, FDA (Confirmed)
Introduced by: G. Steven Burrill, CEO, Burrill & Company (Confirmed)
2:15 – 3:30 p.m.
Panel: Personalized Medicine and its impact on Healthcare Reform and Reimbursement Policy
With healthcare reform momentum in the United States building, to what extent will personalized medicine’s adoption become part of any revamped system? Championing the reform effort has been President Barack Obama, who has spoken repeatedly of the importance of getting the right treatment to the right person to improve outcomes as well as cost-efficiency. Any reform of healthcare will also include taking a hard look at the reimbursement industry, but why have many in this industry been slow to recognize the promise of personalized medicine? And how will traditional health insurance make the transition from sickness to wellness? Questions the panel will address include: What role will personalized medicine play in healthcare reform and will reimbursement policy accelerate or retard the field’s growth?
- Dr. Eric Book, Chief Medical Officer, Tethys Bioscience (Confirmed)
- Dr. Felix Frueh, VP, R&D Personalized Medicine, Medco Health (Confirmed)
- Dr. William T. McGivney, CEO, National Comprehensive Cancer Network (Confirmed)
Moderator: Christopher Wasden, Strategy & Innovation, PWC (Confirmed)
3:30 – 4:00 p.m.
4:00 – 5:00 p.m.
Keynote Presentation: “Health Technology Acceleration and Convergence: Implications for Personalized Medicine”
Dr. George Poste, DVM, PhD, Chief Scientist, Complex Adaptive Systems Initiative; Regents' Professor and Del E. Webb Distinguished Professor of Biology, Arizona State University (Confirmed)
Meeting Wrap-Up (Day One)
G. Steven Burrill, CEO, Burrill & Company (Confirmed)
5:00 – 6:30 p.m.
Tuesday, November 10, 2009
Day 2 Focus: Commercialization, Global Efforts, Country Adoption
7:30 – 8:15 a.m.
8:15 – 8:45 a.m.
- DiaGenic: a leader in discovery and development of diagnostic tests based on peripheral gene expression profiling.
- DermTech: a biotechnology company specializing in the development and validation of molecular tests using specimens derived from the skin.
8:45 – 9:45 a.m.
Stephen A Williams, Chief Medical Officer, Somalogic Inc. (Confirmed)
Discussion with: Ann Hanham, Managing Director, Burrill & Company (Confirmed)
9:45 – 10:00 a.m.
10:00 – 11:15 a.m.
Panel: Is personalized medicine the next boom for investors?
Is personalized medicine a good investment? Where are the examples of return? In the current economic climate, will there be sufficient capital to foster entrepreneurship in personalized medicine? What are investors looking for when they review the business plans of prospective companies looking for funding?
- Brent Ahrens, General Partner, Canaan Partners (Confirmed)
- Michael Shuster, PhD, Partner, Fenwick & West LLP (Confirmed)
- Sue Siegel, General Partner, Mohr Davidow Ventures (Confirmed)
- Risa Stack, Partner, KPCB (Confirmed)
Moderator: G. Steven Burrill, CEO, Burrill & Company (Confirmed)
11:15 – 12:15 p.m.
Keynote Presentation: “The $1,000 Genome - when will it arrive and how will it transform medicine?"
Dr. Leroy Hood, MD, PhD, President, Institute for Systems Biology (Confirmed)
12:15 – 1:15 p.m.
1:15 – 2:30 p.m.
Panel: Personalized Medicine - Global Initiatives and Perspectives
Many countries are making personalized medicine a priority and have introduced favorable policies and set aside specific funding to encourage research and investments to capitalize on national strengths. In addition to building competitive advantage, many countries are also collaborating with others on a variety of global personalized medicine research initiatives to carry out research into the biology and causes of diseases of common concern such as cancer. This session will examine the global efforts that are ongoing and how these initiatives will speed up the adoption and impact of personalized medicine.
- Honorable Peter Beattie BA LLB MA, Trade and Investment Commissioner - The Americas, Queensland Government (Confirmed)
- Dr. Richard W. Barker, Director General, Association of the British Pharmaceutical Industry (Confirmed)
- Dr. Stephen Little, CEO, DxS Diagnostic Innovations(Confirmed)
Moderators: G. Steven Burrill, CEO, Burrill & Company (Confirmed)
Garrett Vygantas, MD, Director, Burrill & Company (Confirmed)
2:30 – 2:45 p.m.
2:45 – 4:15 p.m.
- Caprion Proteomics: a leading provider of proteomics-based services to the pharmaceutical and biotech industries
- Alethia Biotherapeutics: focusing on discovering tissue specific disease targets and developing monoclonal antibodies for use as therapeutics
- Myca Health: a leader and innovator in web-based health care platforms for health practices
- Prognomix: focused on the discovery of genetic signatures associated with the complications of Type II Diabetes
- Spartan Bioscience: a molecular diagnostics company that develops, manufactures, and markets DNA analyzers for on-demand applications
- Pharmacogenomics Center: a partnership between the University of Montreal, the Montreal Heart Institute and Genome Québec, the Centre provides expertise in pharmacogenomic and clinical genetic research (including statistical genetics, ethical, legal, social and pharmaco-economics issues), pharmacology, and proteomics.